Skinny, Inc. Part 1: The Canadian connection to Ozempic
Dr. Daniel Drucker’s research helped pave the way for Ozempic, the blockbuster GLP-1 class drug. The endocrinologist has been researching the effects on Ozempic’s active ingredient semaglutide in the body for decades.
Today, he’ll show us around his lab and explain how a stout lizard kept in a freezer helped unlock the science behind a drug taken by more than a million Canadians.
Then, health reporter Kelly Grant tells us about rising obesity rates in Canada, and we’ll hear from a doctor who prescribes GLP-1s – and a patient who takes them.
This episode originally aired February 23, 2026…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.